Wellcome Sanger Institute, Hinxton, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Wellcome Sanger Institute, Hinxton, UK; MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK.
Lancet Infect Dis. 2019 Sep;19(9):943-951. doi: 10.1016/S1473-3099(19)30392-5. Epub 2019 Jul 22.
A multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambodia in 2008-13, causing high rates of treatment failure with the frontline combination therapy dihydroartemisinin-piperaquine. Here, we report on the evolution and spread of KEL1/PLA1 in subsequent years.
For this genomic epidemiology study, we analysed whole genome sequencing data from P falciparum clinical samples collected from patients with malaria between 2007 and 2018 from Cambodia, Laos, northeastern Thailand, and Vietnam, through the MalariaGEN P falciparum Community Project. Previously unpublished samples were provided by two large-scale multisite projects: the Tracking Artemisinin Resistance Collaboration II (TRAC2) and the Genetic Reconnaissance in the Greater Mekong Subregion (GenRe-Mekong) project. By investigating genome-wide relatedness between parasites, we inferred patterns of shared ancestry in the KEL1/PLA1 population.
We analysed 1673 whole genome sequences that passed quality filters, and determined KEL1/PLA1 status in 1615. Before 2009, KEL1/PLA1 was only found in western Cambodia; by 2016-17 its prevalence had risen to higher than 50% in all of the surveyed countries except for Laos. In northeastern Thailand and Vietnam, KEL1/PLA1 exceeded 80% of the most recent P falciparum parasites. KEL1/PLA1 parasites maintained high genetic relatedness and low diversity, reflecting a recent common origin. Several subgroups of highly related parasites have recently emerged within this co-lineage, with diverse geographical distributions. The three largest of these subgroups (n=84, n=79, and n=47) mostly emerged since 2016 and were all present in Cambodia, Laos, and Vietnam. These expanding subgroups carried new mutations in the crt gene, which arose on a specific genetic background comprising multiple genomic regions. Four newly emerging crt mutations were rare in the early period and became more prevalent by 2016-17 (Thr93Ser, rising to 19·8%; His97Tyr to 11·2%; Phe145Ile to 5·5%; and Ile218Phe to 11·1%).
After emerging and circulating for several years within Cambodia, the P falciparum KEL1/PLA1 co-lineage diversified into multiple subgroups and acquired new genetic features, including novel crt mutations. These subgroups have rapidly spread into neighbouring countries, suggesting enhanced fitness. These findings highlight the urgent need for elimination of this increasingly drug-resistant parasite co-lineage, and the importance of genetic surveillance in accelerating malaria elimination efforts.
Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and UK Department for International Development.
2008-2013 年间,一种名为 KEL1/PLA1 的恶性疟原虫多药耐药共系在柬埔寨传播,导致青蒿琥酯-哌喹联合疗法的一线治疗失败率居高不下。在此,我们报告了 KEL1/PLA1 在随后几年的演变和传播情况。
本基因组流行病学研究分析了通过疟疾基因项目从柬埔寨、老挝、泰国东北部和越南的疟疾患者中采集的 2007 年至 2018 年间的恶性疟原虫临床样本的全基因组测序数据。未发表的新样本由两个大型多地点项目提供:追踪青蒿素耐药性合作研究 II(TRAC2)和大湄公河次区域遗传研究(GenRe-Mekong)项目。通过调查寄生虫之间的全基因组相关性,我们推断了 KEL1/PLA1 群体中共享祖先的模式。
我们分析了 1673 条通过质量过滤的全基因组序列,并确定了 1615 条 KEL1/PLA1 状态。在 2009 年之前,KEL1/PLA1 仅在柬埔寨西部发现;到 2016-2017 年,除老挝外,所有调查国家的 KEL1/PLA1 流行率均上升至 50%以上。在泰国东北部和越南,KEL1/PLA1 超过了最近恶性疟原虫寄生虫的 80%。KEL1/PLA1 寄生虫保持着高度的遗传相关性和低多样性,反映出最近的共同起源。在这个共系内,最近出现了几个具有不同地理分布的高度相关的寄生虫亚群。这三个最大的亚群(n=84、n=79 和 n=47)主要出现在 2016 年以后,均存在于柬埔寨、老挝和越南。这些不断扩大的亚群在 crt 基因中携带新的突变,这些突变发生在包含多个基因组区域的特定遗传背景上。四个新出现的 crt 突变在早期很少见,但到 2016-2017 年变得更为普遍(Thr93Ser,上升到 19.8%;His97Tyr 为 11.2%;Phe145Ile 为 5.5%;Ile218Phe 为 11.1%)。
在柬埔寨出现和传播了几年后,恶性疟原虫 KEL1/PLA1 共系多样化成多个亚群,并获得了新的遗传特征,包括新的 crt 突变。这些亚群迅速传播到邻国,表明其适应性增强。这些发现突显出迫切需要消除这种日益耐药的寄生虫共系,以及遗传监测对加速消除疟疾工作的重要性。
惠康信托基金会、比尔及梅林达·盖茨基金会、英国医学研究理事会和英国国际发展部。